Aerie Pharmaceuticals Inc (NASDAQ:AERI) Expected to Announce Earnings of -$0.87 Per Share

Equities research analysts expect Aerie Pharmaceuticals Inc (NASDAQ:AERI) to announce earnings per share (EPS) of ($0.87) for the current fiscal quarter, according to Zacks. Five analysts have provided estimates for Aerie Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.88) and the highest is ($0.86). Aerie Pharmaceuticals reported earnings of ($1.14) per share during the same quarter last year, which indicates a positive year over year growth rate of 23.7%. The business is scheduled to issue its next earnings report after the market closes on Wednesday, August 7th.

According to Zacks, analysts expect that Aerie Pharmaceuticals will report full-year earnings of ($2.69) per share for the current fiscal year, with EPS estimates ranging from ($2.92) to ($2.34). For the next year, analysts expect that the company will post earnings of ($0.49) per share, with EPS estimates ranging from ($0.86) to $0.03. Zacks’ earnings per share calculations are an average based on a survey of sell-side research analysts that that provide coverage for Aerie Pharmaceuticals.

Aerie Pharmaceuticals (NASDAQ:AERI) last issued its earnings results on Tuesday, May 7th. The company reported ($0.78) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.91) by $0.13. The firm had revenue of $10.85 million for the quarter, compared to the consensus estimate of $12.66 million. Aerie Pharmaceuticals had a negative net margin of 684.56% and a negative return on equity of 93.96%.

AERI has been the topic of several analyst reports. Canaccord Genuity set a $56.00 target price on shares of Aerie Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, June 11th. Needham & Company LLC reiterated a “positive” rating and issued a $74.00 target price on shares of Aerie Pharmaceuticals in a research note on Wednesday, July 10th. Zacks Investment Research upgraded shares of Aerie Pharmaceuticals from a “sell” rating to a “hold” rating and set a $31.00 target price on the stock in a research note on Friday, June 28th. Mizuho set a $77.00 target price on shares of Aerie Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, July 19th. Finally, Piper Jaffray Companies set a $76.00 target price on shares of Aerie Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, July 5th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and ten have issued a buy rating to the company. Aerie Pharmaceuticals has a consensus rating of “Buy” and an average target price of $69.50.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Truvestments Capital LLC purchased a new position in shares of Aerie Pharmaceuticals during the first quarter valued at approximately $33,000. Quantamental Technologies LLC purchased a new position in shares of Aerie Pharmaceuticals during the first quarter valued at approximately $41,000. Oppenheimer Asset Management Inc. purchased a new position in shares of Aerie Pharmaceuticals during the first quarter valued at approximately $47,000. Meeder Asset Management Inc. raised its holdings in shares of Aerie Pharmaceuticals by 134.0% during the first quarter. Meeder Asset Management Inc. now owns 1,060 shares of the company’s stock valued at $50,000 after purchasing an additional 607 shares during the last quarter. Finally, Amundi Pioneer Asset Management Inc. purchased a new position in shares of Aerie Pharmaceuticals during the fourth quarter valued at approximately $105,000.

Shares of NASDAQ AERI traded up $0.15 during midday trading on Friday, hitting $21.59. The stock had a trading volume of 913,351 shares, compared to its average volume of 832,626. The firm’s 50 day moving average is $26.57. The stock has a market cap of $991.41 million, a P/E ratio of -4.64 and a beta of 0.42. Aerie Pharmaceuticals has a 52 week low of $20.88 and a 52 week high of $67.65. The company has a current ratio of 3.47, a quick ratio of 3.27 and a debt-to-equity ratio of 0.06.

About Aerie Pharmaceuticals

Aerie Pharmaceuticals, Inc, an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, retinal diseases, and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.

Featured Story: How to trade on quiet period expirations

Get a free copy of the Zacks research report on Aerie Pharmaceuticals (AERI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.